1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Neurology Clinical Trials: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Neurology Clinical Trials: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Neurology Clinical Trials Market – Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 Overview on world economy
4.3. Industry ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological
10. Neurology Clinical Trials Market
10.1.Overview
10.2.Historical Analysis (2016-2020)
10.2.1.Market Size, Y-o-Y Growth (%) and Market Forecast
11. Neurology Clinical Trials Market Size & Forecast 2022A-2032F
11.1.Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Phase
11.3.1.1.Phase I
11.3.1.2.By Value (USD Million) 2022-2032F
11.3.1.3.Market Share (%) 2022-2032F
11.3.1.4.Y-o-Y Growth (%) 2022-2032F
11.3.1.5.Phase II
11.3.1.6.By Value (USD Million) 2022-2032F
11.3.1.7.Market Share (%) 2022-2032F
11.3.1.8.Y-o-Y Growth (%) 2022-2032F
11.3.1.9.Phase III
11.3.1.10.By Value (USD Million) 2022-2032F
11.3.1.11.Market Share (%) 2022-2032F
11.3.1.12.Y-o-Y Growth (%) 2022-2032F
11.3.1.13.Phase IV
11.3.1.14.By Value (USD Million) 2022-2032F
11.3.1.15.Market Share (%) 2022-2032F
11.3.1.16.Y-o-Y Growth (%) 2022-2032F
11.3.2.By Study Design
11.3.2.1.Interventional
11.3.2.2.By Value (USD Million) 2022-2032F
11.3.2.3.Market Share (%) 2022-2032F
11.3.2.4.Y-o-Y Growth (%) 2022-2032F
11.3.2.5.Observational
11.3.2.6.By Value (USD Million) 2022-2032F
11.3.2.7.Market Share (%) 2022-2032F
11.3.2.8.Y-o-Y Growth (%) 2022-2032F
11.3.2.9.Expanded Access
11.3.2.10.By Value (USD Million) 2022-2032F
11.3.2.11.Market Share (%) 2022-2032F
11.3.2.12.Y-o-Y Growth (%) 2022-2032F
11.3.3.By Indication
11.3.3.1.Epilepsy
11.3.3.2.By Value (USD Million) 2022-2032F
11.3.3.3.Market Share (%) 2022-2032F
11.3.3.4.Y-o-Y Growth (%) 2022-2032F
11.3.3.5.Parkinson's Disease (PD)
11.3.3.6.By Value (USD Million) 2022-2032F
11.3.3.7.Market Share (%) 2022-2032F
11.3.3.8.Y-o-Y Growth (%) 2022-2032F
11.3.3.9.Huntington's Disease
11.3.3.10.By Value (USD Million) 2022-2032F
11.3.3.11.Market Share (%) 2022-2032F
11.3.3.12.Y-o-Y Growth (%) 2022-2032F
11.3.3.13.Stroke
11.3.3.14.By Value (USD Million) 2022-2032F
11.3.3.15.Market Share (%) 2022-2032F
11.3.3.16.Y-o-Y Growth (%) 2022-2032F
11.3.3.17.Traumatic Brain Injury (TBI)
11.3.3.18.By Value (USD Million) 2022-2032F
11.3.3.19.Market Share (%) 2022-2032F
11.3.3.20.Y-o-Y Growth (%) 2022-2032F
11.3.3.21.Amyotrophic Lateral Sclerosis (ALS)
11.3.3.22.By Value (USD Million) 2022-2032F
11.3.3.23.Market Share (%) 2022-2032F
11.3.3.24.Y-o-Y Growth (%) 2022-2032F
11.3.3.25.Muscle Regeneration
11.3.3.26.By Value (USD Million) 2022-2032F
11.3.3.27.Market Share (%) 2022-2032F
11.3.3.28.Y-o-Y Growth (%) 2022-2032F
11.3.3.29.Others
11.3.3.30.By Value (USD Million) 2022-2032F
11.3.3.31.Market Share (%) 2022-2032F
11.3.3.32.Y-o-Y Growth (%) 2022-2032F
12. North America Neurology Clinical Trials Market Size & Forecast 2022A-2032F
12.1.Overview
12.2.Key Findings
12.3.Market Segmentation
12.3.1.By Phase
12.3.2.By Study Design
12.3.3.By Indication
12.4.Country
12.4.1.United States
12.4.2.Canada
13. Europe Neurology Clinical Trials Market Size & Forecast 2022A-2032F
13.1.Overview
13.2.Key Findings
13.3.Market Segmentation
13.3.1.By Phase
13.3.2.By Study Design
13.3.3.By Indication
13.4.Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4.Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia Neurology Clinical Trials Market Size & Forecast 2022A-2032F
14.1.Overview
14.2.Key Findings
14.3.Market Segmentation
14.3.1.By Phase
14.3.2.By Study Design
14.3.3.By Indication
14.4.By Country
14.4.1.India
14.4.2.China
14.4.3.South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15. Middle East and Africa Neurology Clinical Trials Market Size & Forecast 2022A-2032F
15.1.Overview
15.2.Key Findings
15.3.Market Segmentation
15.3.1.By Phase
15.3.2.By Study Design
15.3.3.By Indication
15.4.Country
15.4.1.Israel
15.4.2.GCC
15.4.3.North Africa
15.4.4.South Africa
15.4.5.Rest of Middle East and Africa
16. Latin America Neurology Clinical Trials Market Size & Forecast 2022A-2032F
16.1.Overview
16.2.Key Findings
16.3.Market Segmentation
16.3.1.By Phase
16.3.2.By Study Design
16.3.3.By Indication
16.4.Country
16.4.1.Mexico
16.4.2.Brazil
16.4.3.Rest of Latin America
17. Competitive Landscape
17.1.Company market share, 2021
17.2.Key player overview
17.3.Key stakeholders
18. Company Profiles
18.1.Abbott Laboratories
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2.Key Clients
18.1.4.3.Market Share
18.1.4.4.Recent News & Development (Last 3 Yrs.)
18.1.4.5.Executive Team
18.2.Novartis
18.3.Labcorp Drug Development
18.4.Charles River Laboratories
18.5.GlaxoSmithKline
18.6.Pfizer
18.7.Aurora healthcare
18.8.Medpace
18.9.Syneous Health
18.10.Icon Plc
18.11.Biogen
18.12.Amgen
18.13.Merck
18.14.AstraZeneca
18.15.Bristol Myers Squibb
18.16.Other Prominent Players
19. Appendix
20. Consultant Recommendation
Select License Type
Our Clients
We have been working with some Fortune 500+ clients
.png){kind=icon}
